BioCentury | Dec 8, 2008
Clinical News

BF-Derm1: Completed Phase II enrollment

Biofrontera completed enrollment of 51 patients in the placebo-controlled portion of a German and Russian Phase II trial evaluating BF-Derm1 for 8 weeks. Biofrontera AG (Xetra:B8F), Leverkusen, Germany Product: BF-Derm1 Business: Dermatology Molecular target: Histidine...
BioCentury | Aug 13, 2007
Finance

Potential Phase III leadership

Potential Phase III leadership Company Product Indication 4SC SC12267 Rheumatoid arthritis (RA) Biofrontera BF-37 Atopic dermatitis Biofrontera BF-derm 1 Chronic urticaria Evotec EVT 201 Insomnia MediGene EndoTAG-1 Breast, pancreatic cancer MediGene NV1020 Liver metastases of...
BioCentury | Nov 1, 2006
Financial News

Biofrontera raises EUR 6.7M, lists on Duesseldorf exchange

Biofrontera (DSE:B8F) raised EUR 6.7 million ($8.5 million) last week through a private placement of 440,000 shares at EUR 15. The shares began trading on Monday on the Duesseldorf Stock Exchange under the ticker B8F....
BioCentury | Jun 27, 2006
Financial News

Biofrontera planning IPO

Biofrontera (Leverkusen, Germany) plans to sell up to 1.9 million shares in an IPO on the Frankfurt Stock Exchange on July 6. The dermatology company has not yet disclosed how much money it hopes to...
BioCentury | Sep 19, 2005
Finance

Ebb & Flow

FDA's accidental posting of briefing documents for Celgene's Revlimid a day ahead of schedule gave alert investors an afternoon of arbitrage last Monday. Typically, the agency posts its clinical and statistical reviews of a compound...
BioCentury | Sep 13, 2005
Company News

Biofrontera acquires dermatology compound

Biofrontera (Leverkusen, Germany) acquired from Switch (Neuried, Germany) an undisclosed compound to treat dermatological indications. Biofrontera , which will develop the compound for atopic dermatitis, said the compound is marketed for indications outside of dermatology. Biofrontera...
BioCentury | Sep 5, 2005
Finance

Ebb & Flow

Chiron's six independent directors clearly opened the door to Novartis' proposed acquisition of the 58% of CHIR it doesn't already own. However, NVS can hardly have failed to notice that CHIR is looking very inexpensive....
BioCentury | Sep 1, 2005
Financial News

Biofrontera raises EUR 20 million

Biofrontera (Leverkusen, Germany) raised EUR 20 million ($24.6 million) through a private placement of 200,000 five-year partial debentures at EUR 100. The debentures bear 8% interest and convert into stock at EUR 16.13. If the...
BioCentury | Oct 4, 2004
Finance

The brave Atlantic alliance

While European investors continue to put their money into the U.S., a change in the Paris Stock Exchange rules is making it easier for U.S. investors to hunt for bargains in Europe. NicOx (NM:Nicox) last...
BioCentury | Oct 4, 2004
Company News

Biofrontera Pharmaceuticals Holding AG, DNAPrint deal

DNAP will invest E20 million ($24.5 million) over the next two years for a 51.4% stake in Biofrontera in the form of series B shares. The companies also entered a JV to integrate Biofrontera's drug...
Items per page:
1 - 10 of 11